Quarterly report · Q1
4671.TEDINET S100RP4T
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.6bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥46.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.6bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥249m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥681m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥303m | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥769m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥292m | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥748m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥124m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥124m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥37.1bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥38.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥38.2bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.2bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥12.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥26.0bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥23.6bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.6bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥11.07 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥215.29 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.32 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥11.05 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥214.03 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.25 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 69.7% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.5% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥145m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥6.6bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥6.6bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥348m |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥55m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥190m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥190m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥8m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥10.6bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥10.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥395m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥108m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.6bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.6bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥855m |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥102m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥102m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥73m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥789m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 358
| Item | Context | Value | Unit |
|---|---|---|---|
| Other ioa | Prior1YearInstant | 2471000000 | JPY |
| Other ioa | CurrentQuarterInstant | 2370000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -5000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -4000000 | JPY |
| Investments and other assets | Prior1YearInstant | 5085000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 6509000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 16187000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 17429000000 | JPY |
| Assets | Prior1YearInstant | 38893000000 | JPY |
| Assets | CurrentQuarterInstant | 37119000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 4374000000 | JPY |
| Notes and accounts payable trade | CurrentQuarterInstant | 5141000000 | JPY |
| Short term loans payable | Prior1YearInstant | － | JPY |
| Short term loans payable | CurrentQuarterInstant | 300000000 | JPY |
| Current portion of long term loans payable | Prior1YearInstant | 2340000000 | JPY |
| Current portion of long term loans payable | CurrentQuarterInstant | － | JPY |
| Income taxes payable | Prior1YearInstant | 181000000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 175000000 | JPY |
| Provision cl | Prior1YearInstant | 557000000 | JPY |
| Provision cl | CurrentQuarterInstant | 197000000 | JPY |
| Other cl | Prior1YearInstant | 2111000000 | JPY |
| Other cl | CurrentQuarterInstant | 2629000000 | JPY |
| Current liabilities | Prior1YearInstant | 9564000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 8444000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 1849000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 1833000000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 134000000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 135000000 | JPY |
| Other ncl | Prior1YearInstant | 752000000 | JPY |
| Other ncl | CurrentQuarterInstant | 744000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 2736000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 2712000000 | JPY |
| Liabilities | Prior1YearInstant | 12301000000 | JPY |
| Liabilities | CurrentQuarterInstant | 11156000000 | JPY |
| Capital stock | Prior1YearInstant | 3371000000 | JPY |
| Capital stock | CurrentQuarterInstant | 3371000000 | JPY |
| Capital surplus | Prior1YearInstant | 3670000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 3669000000 | JPY |
| Retained earnings | Prior1YearInstant | 19025000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 18386000000 | JPY |
| Treasury stock | Prior1YearInstant | -94000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -90000000 | JPY |
| Shareholders equity | Prior1YearInstant | 25973000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 25337000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 535000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 546000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 535000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 546000000 | JPY |
| Subscription rights to shares | Prior1YearInstant | 82000000 | JPY |
| Subscription rights to shares | CurrentQuarterInstant | 78000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |